Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension

NCT ID: NCT04663217

Last Updated: 2024-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-01

Study Completion Date

2023-11-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the exercise profile in pulmonary hypertension patients with either pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension or pulmonary hypertension due to left heart disease and in disease control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a dual-center observational prospective study in patients with pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension due to left heart disease. Patients undergoing right heart catheterisation due to dyspnoe with invasive exclusion of pulmonary hypertension will be recruited as disease control.

The study comprises a 1-day screening period, followed by a right heart catheterization with exercise challenge.

The study starts with screening, information of the patients and Informed Consent Form signature at day -1. Screening and inclusion of the patient can be performed on the same day. On the day of the planned right heart catheterization based on clinical grounds, exercise right heart catheterisation (RHC) using Swan-Ganz and/or Conductance catheters with simultaneous echocardiography will be performed. End of study is defined as a complete exercise RHC. Adverse events will be assessed until 1 day after the exercise RHC.

After placement of the Swan-ganz or Conductance catheter patients will undergo an exercise challenge using the following protocol in semi-supine position until exhaustion:

* Incremental workload increase of 20Watt every 2-4 min.
* For patients not able to start a 20 Watt, initial workload can be adjusted to a minimum of 5 Watt with 5 Watt increase every 2-4 min until exhaustion
* Maximal exercise duration is 10-12 minutes
* Symptoms of dyspnoea during exercise will be rated by subjects at baseline, after 6 minutes and at maximum according to the Borg perceived dyspnoea (0-10) scale.

Simultaneously, echocardiography and lung ultrasound will be performed before exercise (baseline), after 6 minutes of exercise and at maximum.

After assessment of right ventriclure pressure-volume loops during maximum exercise, guided by echocardiographic the conductance catheter will be placed in the right atrium to obtain right atrium pressure-volume loops during maximum exercise.

Optional, the exercise RHC will be performed without the Conductance catheter and only with the Swan-Ganz catheter. In this case, pressure values and cardiac output will be measured using the thermodilution method, averaging 3-5 measurements at baseline, 6 minutes and maximum. Detailed assessment of right atrial pressure curves (with a and v wave) will be performed at baseline, 6 minutes and maximum exercise.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Pulmonary Hypertension, Pulmonary Arterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary arterial hypertension

Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.

Exercise

Intervention Type OTHER

After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Pulmonary hypertension due to left heart disease

Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.

Exercise

Intervention Type OTHER

After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Chronic thromboembolic pulmonary hypertension

Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.

Exercise

Intervention Type OTHER

After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Control

Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.

Exercise

Intervention Type OTHER

After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of pulmonary arterial hypertension (World Health Organization group 1)
* Pulmonary hypertension due to left heart disease (World Health Organization group 2)
* Chronic thromboembolic pulmonary hypertension (World Health Organization group 4)
* Invasive exclusion of pulmonary hypertension
* Age ≥ 18 years
* Planned right heart catheterization based on clinical grounds
* Stable specific PAH medications
* Ability to undergo cycle ergometry
* Signed informed consent

Exclusion Criteria

* Other etiologic groups of pulmonary hypertension (World Health Organization group 3, 5)
* Unstable or severe coronary artery disease
* Uncontrolled arterial hypertension
* Left ventricular ejection fraction \< 30%
* Severe congenital or acquired valvular or myocardial disease
* Progressive left heart failure
* History of severe ventricular arrhythmias
* Severe, terminal renal impairment
* Severe obstructive or restrictive lung disease
* Severe lung emphysema or interstitial lung disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Giessen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richter J Manuel, MD

Role: PRINCIPAL_INVESTIGATOR

UKGM Giessen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kerckhoff-Klinik

Bad Nauheim, Hesse, Germany

Site Status

University of Giessen

Giessen, Hesse, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Yogeswaran A, da Rocha BB, Rako ZA, Kaufmann SJ, Schafer S, Kremer N, Ghofrani HA, Seeger W, Tello K. Physiological mechanisms behind respiratory variations in right atrial pressure in pulmonary hypertension. Sci Rep. 2024 May 31;14(1):12547. doi: 10.1038/s41598-024-61825-6.

Reference Type DERIVED
PMID: 38822042 (View on PubMed)

Rako ZA, Yogeswaran A, Lakatos BK, Fabian A, Yildiz S, da Rocha BB, Vadasz I, Ghofrani HA, Seeger W, Gall H, Kremer NC, Richter MJ, Bauer P, Tedford RJ, Naeije R, Kovacs A, Tello K. Clinical and functional relevance of right ventricular contraction patterns in pulmonary hypertension. J Heart Lung Transplant. 2023 Nov;42(11):1518-1528. doi: 10.1016/j.healun.2023.07.004. Epub 2023 Jul 13.

Reference Type DERIVED
PMID: 37451352 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AZ 11716

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Exercise Effects on Atrial Fibrillation
NCT06607510 NOT_YET_RECRUITING NA
The SMARTEX Heart Failure Study
NCT00917046 COMPLETED NA
Exercise Training to Atrial Fibrillation
NCT04508478 ACTIVE_NOT_RECRUITING NA